Results 91 to 100 of about 30,023 (217)

A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties [PDF]

open access: yes, 2015
INTRODUCTION: Activation of cyclooxygenase (COX)/prostaglandin and nuclear factor κB (NFκB) pathways can promote breast tumor initiation, growth, and progression to drug resistance and metastasis.
Gregory R. J. Thatcher   +5 more
core   +1 more source

Dimethyl Fumarate Attenuates Methotrexate Hepatotoxicity in Mice Via the Nrf2/HO-1/Anti-Apoptotic Signaling Pathway [PDF]

open access: diamond, 2023
Mohammad Ali Karimi   +5 more
openalex   +1 more source

Kaempferitrin's Dual Assault: Inducing Apoptosis and Ferroptosis in Diffuse Large B‐Cell Lymphoma via NF‐κB Inactivation

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common non‐Hodgkin lymphoma and is an aggressive and highly heterogeneous tumor. Kaempferitrin (KPF) is a natural flavonoid glycoside that exerts a protective role in multiple human tumors. However, the impact of KPF on DLBCL remains unclear.
Han‐Shuo Zhang   +3 more
wiley   +1 more source

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases [PDF]

open access: yes, 2019
The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (KEAP1), are critical in the maintenance of redox, metabolic and protein ...
Attucks, Otis C.   +10 more
core   +2 more sources

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing

open access: yesThe Journal of Pathology, EarlyView.
Abstract Netherton syndrome (NS) is a rare, severe, and often life‐threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities.
Eleni Zingkou   +3 more
wiley   +1 more source

New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis [PDF]

open access: green, 2022
Ma Carmen Ocaña   +8 more
openalex   +1 more source

Protective Role for Itaconate During Inhaled Allergen Challenge

open access: yesAllergy, EarlyView.
Itaconate levels decrease in sputum following allergen inhalation in mild asthmatics, suggesting a dynamic metabolic response to airway challenge. Genetic deletion of Acod1 in mice did not alter airway inflammation or remodelling in response to chronic HDM exposure.
Gesa J. Albers   +16 more
wiley   +1 more source

CRISPR‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death

open access: yesThe FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9 screen identified H3K27 methylation as a key regulator of T‐cell lymphoma sensitivity to dimethyl fumarate (DMF). Specifically, inhibition of enhancer of zeste homolog 2 (EZH2) enhanced DMF‐induced cell death in malignant T cells. These results provide functional evidence for the role of EZH2 in modulating drug sensitivity and
Jan P. Teubner   +17 more
wiley   +1 more source

Desulfovibrio paquesii sp. nov., a hydrogenotrophic sulfate-reducing bacterium isolated from a synthesis-gas-fed bioreactor treating zinc- and sulfate-rich wastewater [PDF]

open access: yes, 2009
A hydrogenotrophic, sulfate-reducing bacterium, designated strain SB1(T), was isolated from sulfidogenic sludge of a full-scale synthesis-gas-fed bioreactor used to remediate wastewater from a zinc smelter. Strain SB1(T) was found to be an abundant micro-
Doesburg, W., van   +5 more
core   +2 more sources

Evaluation of the effect of dimethyl fumarate on human bone marrow-derived mesenchymal stem cells using bottom-up proteomics [PDF]

open access: green, 2023
Maryam Adelipour   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy